{
    "nct_id": "NCT04720976",
    "official_title": "A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor. Some cohorts must meet specific expression or gene mutation where indicated\n* Sufficient organ function\n* Participants must have at least 1 measurable lesion as defined by RECIST v1.1\n* Must be able to provide an archived tumor sample\n* ECOG performance status score of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of cancer that is histologically distinct from the cancers under study\n* Active or untreated central nervous system (CNS) metastases\n* History of pneumonitis or interstitial lung disease (ILD)\n* Has active hepatitis B, hepatitis C infection, HIV\n* Any severe and/or uncontrolled medical conditions\n* LVEF â‰¤50%\n* QTcF >470 msec",
    "miscellaneous_criteria": ""
}